Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Avalanche Biotechnologies Inc.

Ocular protein factories for eye diseases

This article was originally published in Start Up

Executive Summary

Anti-angiogenesis drugs Lucentis and Eylea have proved game changers in the treatment of wet age-related macular degeneration, but to stave off AMD blindness, patients must submit every four to eight weeks for the rest of their lives to costly, painful, and potentially dangerous injections in the eyeball. Avalanche Biotechnologies Inc. hopes to replace that chronic regimen with just a single therapeutic gene injection that will set what it describes as an ocular protein factory into production that will stave off AMD pathology long term.


Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts